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5-Hydroxytryptamine 2A (5-HT2A) serotonin receptors
are important for a variety of functions including vas-
cular smooth muscle contraction, platelet aggregation,
and the modulation of perception, cognition, and emo-
tion. In a search for 5-HT2A receptor-interacting pro-
teins, we discovered that caveolin-1 (Cav-1), a scaffold-
ing protein enriched in caveolae, complexes with 5-HT2A
receptors in a number of cell types including C6 glioma
cells, transfected HEK-293 cells, and rat brain synaptic
membrane preparations. To address the functional sig-
nificance of this interaction, we performed RNA inter-
ference-mediated knockdown of Cav-1 in C6 glioma
cells, a cell type that endogenously expresses both
5-HT2A receptors and Cav-1. We discovered that the in
vitro knockdown of Cav-1 in C6 glioma cells nearly abol-
ished 5-HT2A receptor-mediated signal transduction as
measured by calcium flux assays. RNA interference-me-
diated knockdown of Cav-1 also greatly attenuated en-
dogenous Gq-coupled P2Y purinergic receptor-medi-
ated signaling without altering the signaling of PAR-1
thrombin receptors. Cav-1 appeared to modulate 5-HT2A
signaling by facilitating the interaction of 5-HT2A recep-
tors with Gq. These studies provide compelling evi-
dence for a prominent role of Cav-1 in regulating the
functional activity of not only 5-HT2A serotonin recep-
tors but also selected Gq-coupled receptors.
The serotonin (5-hydroxytryptamine) 2A receptor (5-HT2A),
1
a member of the “rhodopsin-like” (family A) G-protein-coupled
receptors (GPCRs) (1), mediates the actions of many (2) but not
all hallucinogens (3, 4) and is the target of a number of com-
monly prescribed therapeutic agents, including atypical anti-
psychotics, antidepressants, and anxiolytics (5). As with other
GPCRs, elucidating the mechanisms of signal transduction and
regulation for 5-HT2A receptors is likely to be of great relevance
for the rational design of novel medications (6–8). In particu-
lar, one point where the regulation of GPCR signaling con-
verges is the endocytic pathway (8, 9), and therefore, this
pathway is likely to play a role in various functions involving
the 5-HT2A receptor.
Prototypically, GPCRs are internalized via an integrated
process involving arrestins and G-protein receptor kinases, a
process that has been most elegantly elucidated for the -ad-
renergic receptor (10), although many other proteins are also
involved in the intracellular trafficking of GPCRs (6, 11). For
example, we have uncovered a cell type-specific, arrestin-inde-
pendent, dynamin-dependent mechanism of 5-HT2A receptor
regulation (12, 13). In light of recent studies demonstrating
that -adrenergic receptors, in particular, are associated with
caveolae and caveolin in their native milieu (14, 15), we hy-
pothesized that 5-HT2A receptors might also be associated with
caveolae-enriched membrane specializations and that this in-
teraction might functionally modulate 5-HT2A-mediated signal
transduction.
Caveolae are small flask-shaped invaginations of the plasma
membrane (16) containing high levels of cholesterol and glyco-
sphingolipids and are initially characterized by the presence of
the protein Cav-1 (17). Caveolae differ biochemically from other
specialized subdomains of the plasma membrane (16). A family
of caveolin proteins has been identified that includes caveo-
lin-1, caveolin-2, and caveolin-3 (Cav-1, -2, and –3, respectively
(18)), with Cav-1 and Cav-2 being expressed ubiquitously.
Caveolae function is critically dependent on Cav-1 because
caveolae are not formed in Cav-1 knockout mice (19); con-
versely, caveolin-deficient cells acquire caveolae when trans-
fected with Cav-1 (20).
In prior studies, we found that caveolae were not normally
required for the membrane targeting of 5-HT2A receptors het-
erologously expressed in either NIH 3T3 (21) or HEK-293 (12)
cells, although a recent study (22) indirectly implicated caveo-
lae in 5-HT2A-mediated signal transduction in vascular smooth
muscle cells. Even though prior studies have not implicated
Cav-1 as a modulator of 5-HT2A receptor signaling, Cav-1 has
been indirectly implicated as a regulator of GPCR signaling via
unknown mechanisms (19).
Here we report that both transiently transfected 5-HT2A
receptors associate with Cav-1 in HEK-293 cells and endog-
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enously expressed 5-HT2A receptors associate with Cav-1 in C6
glioma cells and rat brain synaptic membrane preparations.
We also report that the RNAi-mediated knockdown of Cav-1
has profound functional consequences for 5-HT2A-mediated sig-
nal transduction in C6-glioma cells, a cell type that endog-
enously expresses both Cav-1 and 5-HT2A receptors. Most im-
portantly, screening of C6 glioma cells for other Gq-coupled
receptors showed that knockdown of Cav-1 modulated the sig-
naling of purinergic receptors but not of PAR-1 thrombin re-
ceptors in C6 glioma cells, suggesting that only a subset of
Gq-coupled receptors is regulated by Cav-1.
EXPERIMENTAL PROCEDURES
cDNA Constructs and Reagents—The construct coding for FLAG-
tagged wild type (wt) rat 5-HT2A receptor (FLAG-5-HT2A) (12) was
modified by addition of an amino-terminal and cleavable signal peptide
sequence (MKTIIALSYIFCLVFA; see Ref. 23) from influenza hemag-
glutinin and has been described elsewhere (24). The caveolin-1-myc
cDNA was a gift from Gary Landreth (Case Western Reserve Univer-
sity), and the constitutively active Gq mutant (Q229L) was from David
Siderovski (University of North Carolina, Chapel Hill). Thrombin re-
ceptor-activating peptide (TRAP) was a gift from Paul Di Corleto
(Lerner Research Institute, Case Western Reserve University). All con-
structs containing inserts in the appropriate orientation were verified
FIG. 1. Cav-1 co-localizes with native 5-HT2A receptors independently of agonist exposure. For these experiments HEK-293 cells were
transiently co-transfected with FLAG-5-HT2A  cav-1-myc (A–F). At 48 h following transfection, cells were placed in serum-free media for a
minimum of 18 h and then exposed to vehicle (A–C) or 10 M 5-HT (D–F) for 5 min. This was followed by dual-label immunofluorescent confocal
microscopy (see “Experimental Procedures”). Representative images from one of three independent experiments are shown. FLAG-tagged native
5-HT2A receptors are shown in the red channel (A and D) and cav-1-myc is shown in the green channel (B and E). The merged images are in C and
F. Scale bars are shown in all panels. G shows the quantitative analysis of percent receptor internalization in the presence and absence of Cav-1
in response to vehicle and or agonist 5-HT (10 M) for 5min. **, p  0.05; ns, no statistically significant difference.
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by automated sequencing (Cleveland Genomics, Cleveland, OH). 5-Hy-
droxytryptamine (5-HT) creatinine sulfate, ATP, and chlorpromazine
were acquired from Sigma. [3H]Ketanserin and myo-[3H]inositol were
purchased from PerkinElmer Life Sciences.
Transfection of HEK-293 Cells and C6 Glioma Cells—Human embry-
onic kidney 293 (HEK-293) cells and C6 glioma cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bo-
vine serum, 1 mM sodium pyruvate, penicillin (100 units/ml), and strep-
tomycin (100 mg/ml) (Invitrogen) at 37 °C and 5% CO2. Transient
transfection of HEK-293 cells with FuGENE 6™ (Roche Applied Sci-
ence) using a FuGENE to DNA ratio of 5:1 was performed according to
the manufacturer’s recommendations. A total of 6 g of DNA was used
in each co-transfection, 3 g of which were FLAG-5-HT2A receptor or
constitutively active G-protein (Gq*) and 3 g of which were DNA
encoding cav-1-myc or GFP. In case of triple transfections with FLAG-
5-HT2A receptor, cav-1-myc, Gq, and/or GFP, 2 g of each plasmid
DNA was used. C6 glioma cells were transfected using Lipo-
fectAMINE2000 (Invitrogen). A total of 24 g of DNA was used with 60
l of LipofectAMINE as recommended by the manufacturer.
Immunocytochemistry, Agonist-mediated Internalization, and Image
Quantification—Dual-labeling immunocytochemistry was performed
essentially as described before (12), and images of cells treated with
vehicle and or agonist 5-HT (10 M) were acquired digitally using a
Zeiss 410 confocal microscope (Oberkochen, Germany) without satura-
tion of pixel intensities. Images were subsequently analyzed for percent
receptor internalization using MetaView software (Universal Imaging)
as detailed previously (24).
Co-immunoprecipitation and Immunoblot—Co-immunoprecipitation
and immunoblotting were performed essentially as detailed previously
(24, 25). For visualization and immunoprecipitation of Cav-1, a poly-
clonal Cav-1 antibody (1:2000) (BD Transduction Laboratories) was
used, and a monoclonal M2-anti-FLAG antibody preconjugated to aga-
rose beads was used to immunoprecipitate FLAG-tagged 5-HT2A recep-
tors. Wheat germ agglutinin (WGA) preconjugated to agarose beads
(Sigma) was used to concentrate native 5-HT2A receptors from C6
glioma cells after solubilization in 1.5% CHAPS. A rabbit polyclonal
FLAG antibody (1:1500) (Sigma) was used to detect FLAG-5-HT2A
receptors. A monoclonal mouse Cav-1 antibody and protein A/G-agarose
were used to co-immunoprecipitate native receptor and Cav-1 from C6
glioma cells and rat brain synaptic membrane preparation. Rat brain
synaptic membranes were prepared from rat frontal cortex as described
previously (26). The native 5-HT2A receptor was detected by using a
polyclonal 5-HT2A carboxyl-terminal antibody (27), a gift from Jon
Backstrom (Vanderbilt University). The Gq in immunoprecipitates,
the constitutively active Gq* mutant, and the endogenous wt Gq in
cell lysates were detected by a rabbit polyclonal Gq antibody (1:2000)
(Santa Cruz Biotechnology, Santa Cruz, CA). The immunoblots shown
are representative of at least three independent experiments.
RNAi-mediated Knockdown of Cav-1—A DNA vector-based siRNAi
was designed to stably knock down the expression of Cav-1 in C6 glioma
cells by Genscript. Briefly, a commercial algorithm for designing a
specific siRNA was used (www.genscript.com/ssl-bin/app/rnai). The
length of the siRNA target, GC % range, and the rat cDNA sequence of
Cav-1 were entered into the algorithm and potential siRNA targets
FIG. 2. Cav-1 interacts with native 5-HT2A receptors in HEK-
293 cells. For these experiments, HEK-293 cells were either untrans-
fected (1st and 2nd lanes) or transiently co-transfected with Cav-1 (3rd
and 4th lanes), FLAG-5-HT2A  GFP (5th and 6th lanes; treated with
vehicle), FLAG-5-HT2A  GFP (7th and 8th lanes; treated with 10 M
5-HT for 5 min), FLAG-5-HT2A Cav-1 (9th and 10th lanes; treated
with vehicle), and FLAG-5-HT2A Cav-1 (11th and 12th lanes; treated
with 10 M 5-HT for 5 min). FLAG-tagged native 5-HT2A receptors were
immunoprecipitated (IP) by a monoclonal FLAG antibody conjugated to
Sepharose beads. A polyclonal Cav-1 antibody detected Cav-1myc, and
a polyclonal FLAG antibody on Western blots detected FLAG-5-HT2A. A
polyclonal Gq antibody was used to probe for G-protein as lysate
control. Representative immunoblots (IB) from a single experiment that
has been replicated three times with equivalent results are shown. A
and B, immunoblots from immunoprecipitates. C and D, immunoblots
from cell lysates.
FIG. 3. Cav-1 interacts with native 5-HT2A receptors in C6 gli-
oma cells and rat brain homogenates. For these experiments cell
lysate was prepared from various cell lines, and equivalent amounts of
protein were loaded for all sets in duplicate. Representative immuno-
blot from a single experiment that has been replicated three times with
equivalent results shows the expression of Cav-1 in HEK-293 cells, C6
glioma cells, A75R5, 3T3, and a 3T3 cell line stably expressing 5-HT2A
receptors (GF62; A). B, 5-HT2A receptors were immunoprecipitated (IP)
with Cav-1 in C6 glioma cells. The top panel shows that 5-HT2A recep-
tors were immunoprecipitated by monoclonal Cav-1 antibody (2nd lane)
preconjugated to protein-A/G beads. The 2nd panel from the top shows
robust Cav-1 detection in the immunoprecipitate in the presence of
Cav-1 antibody (2nd lane ()). The 3rd and 4th panels from the top
represents the immunoblots used to detect Cav-1 and 5-HT2A receptor
proteins, respectively, in the total C6 cell lysate. C, 5-HT2A receptors
were immunoprecipitated with Cav-1 from rat brain synaptic mem-
brane preparations. Top panel shows 5-HT2A receptors were co-immu-
noprecipitated with Cav-1 antibody and protein A/G-agarose (2nd lane)
but not with protein A/G-agarose beads alone (). The 2nd panel from
the top shows that Cav-1 was found in the immunoprecipitates (lane 2).
The 3rd and 4th panels from the top shows immunoblots (IB) used to
detect Cav-1 and 5-HT2A receptors, respectively, from total membrane
lysates. Shown are representative immunoblots from a single experi-
ment that has been replicated three times with equivalent results.
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generated. The ranking of siRNA candidates was based on the commer-
cial algorithm. The target sequence CACACAGTTTCGACGGCATCT
(52.38% GC content) was cloned into pRNA-U6.1/neo under the control
of U6 promoter and neomycin selection marker, which was used to
select stable lines. This insert-containing vector was then transfected
into C6 glioma cells, as described above, and the subsequent isolation of
Cav-1-depleted C6 glioma cells was done after selection of stable indi-
vidual clones by using 0.6 mg of geneticin/liter of cell culture medium.
Forty eight clones were individually picked and expanded in selection
medium. After passaging the cells a minimum of three times, lysates
were prepared as described above. To evaluate the stable knockdown of
expression of Cav-1, 10 g of protein lysates were subjected to SDS-
PAGE followed by Western blot analysis probing for Cav-1. The clones,
which showed maximal knockdown, were then maintained in the selec-
tion media containing 0.6 mg of geneticin/liter for further study. Ly-
sates prepared from the clone with maximal knockdown of Cav-1 was
also probed with rabbit polyclonal RSK1 (1:1000) (Santa Cruz Biotech-
nology), mouse monoclonal Cav-2 (1:500) (BD Transduction Laborato-
ries), and polyclonal rabbit Gq antibodies.
Microarray Analysis of C6 Glioma Cells—Nearly confluent plates of
C6 cells were harvested using RNase-free conditions, and a sample
preparation was done by the Gene Expression Array Core Facility at
Case Western Reserve University (www.geacf.net), following methods
recommended by Affymetrix (see Supplemental Material for full de-
tails). Briefly, total RNA was extracted using Trizol (Invitrogen) fol-
lowed by RNA clean up using Qiagen columns that were used to clean
up cDNA and/or RNA as required using the manufacturer’s protocol.
This was followed by cDNA synthesis using an oligo(dT) primer coupled
to T7 RNA polymerase promoter. Reverse transcription of RNA was
done using Superscript II reverse transcriptase in a 20-l reaction at
42 °C for 1 h. Second strand synthesis was carried out immediately in
the presence of Escherichia coli DNA polymerase I, RNase H, and DNA
ligase. The reaction mixture was incubated for 2 h at 16 °C and an
additional 5 min in the presence of T4 DNA polymerase. The reaction
was terminated by addition of EDTA followed by cDNA clean up using
Qiagen columns and storage overnight at 20 °C. In vitro transcription
was used to generate cRNA by using a Bioarray High Yield ENZOkit
(Affymetrix) followed by clean up of RNA samples. Purified in vitro
transcribed cRNA was subjected to fragmentation at 94 °C for 35 min
using 1 fragmentation buffer (40 mM Tris acetate, pH 8.1, 100 mM
KOAc, 30 mM MgOAc) and then placed on ice. Preconditioning for
hybridization was done in 1 hybridization mixture (100 mM MES,1 M
[Na], 20 mM EDTA,0.01% Tween 20). Herring sperm and acetylated
bovine serum albumin were added to a final concentration of 0.1 and 0.5
mg/ml, respectively. A 15-l aliquot of a 20 mixture of in vitro tran-
scripts of bacterial genes bioB, bioC, bioD, and cre were added to the
mixture to give final concentrations of 1.5, 5, 25, and 100 pM, respec-
tively. Control oligonucleotide was added to a final concentration of 50
pM. The amount of fragmentation reaction containing 15 g of cRNA
was added to the mixture, and the remaining volume was made up with
molecular biology grade water. Preconditioning of the array chip was
done in 1 hybridization buffer for 10–15 min at 45 °C with rotation (45
rpm). The preconditioning buffer was then removed from the chip
chamber. Sample hybridization mixture was added to the chip and
hybridized overnight (16 h) at 45 °C with rotation (45 rpm). For post-
hybridization washing and staining, samples were recovered from the
chips and stored in their original vials, and the hybridization chamber
was filled with Buffer A (nonstringent, 6), and hybridization was
overnight (16 h) at 45 °C with rotation (45 rpm) in the sample hybrid-
ization mixture. For post-hybridization washing and staining samples
were recovered from the chips and stored in their original vials. The
hybridization chamber was filled with Buffer A (nonstringent, 6 SSPE
(3 M NaCl, 0.2 M NaH2PO4, 0.02 M EDTA), 0.01% Tween 20). Modules in
the Fluidics Station 400 were primed according to the Affymetrix
protocol.
Samples were loaded into the modules, and washing and staining
were done in stringent buffer B (10 mM MES, 0.1 N [Na], 0.01% Tween
20), which was also used in the protocol. The streptavidin/phyco-
erythrin stain mixture was as follows: 50 mM MES, 0.5 M [Na], 0.025%
Tween 20, 2 mg/ml acetylated bovine serum albumin, 10 g/ml strepta-
vidin phycoerythrin.
The amplification (antibody) solution mixture was as follows: 50 mM
MES, 0.5 M [Na], 0.025% Tween 20, 2 mg/ml acetylated bovine serum
albumin, 0.1 mg/ml normal goat IgG, 3 g/ml biotinylated antibody. All
Chips were scanned twice. For data analysis, images obtained were
converted into Microsoft Excel format using MAS5.0 software (Af-
fymetrix). All chips were scaled to mean target intensity of 1500. Af-
fymetrix present and absent calls were used. For comparisons between
chips, genes with 2-fold differences in expression compared with con-
trols were considered to be significantly differentially expressed.
Radioligand Binding and Second Messenger Studies—Phospho-
inositide hydrolysis assays with the constitutively active Gq* were
performed as described previously (24). Kinetic binding parameters
(Bmax and Kd) were determined from binding assays with [
3H]ketan-
serin, and the results were replicated in at least three separate exper-
iments as detailed previously (24). Phosphoinositide hydrolysis data
were analyzed by nonlinear regression using Prism 3.0 software
(GraphPad, San Diego, CA), and saturation-binding data were analyzed
by using GraphPad Prism. Measurements of p42/44 ERK phosphoryl-
ation were performed as described previously by using total p42/44
ERK for normalization (28). Measurements of intracellular calcium
mobilization on a Molecular Devices Flexstation were performed essen-
tially as described recently (29), with response normalized to the max-
imum with each agonist (5-HT, ATP, and/or TRAP).
Statistical Analysis—Statistical significance for all studies was de-
termined using a Student t test, and statistical significance was defined
as p  0.05.
RESULTS
5-HT2A Receptors Interact with Cav-1—We initially investi-
gated whether 5-HT2A receptors and cav-1-myc can associate in
vitro by co-transfecting HEK-293 cells with FLAG-tagged 5-HT2A
receptors (FLAG-5-HT2A) and Myc-tagged Cav-1 (Cav1-myc). As
shown in Fig. 1, A–C, FLAG-5-HT2A and Cav-1 were co-localized
on both the cell surface of HEK-293 cells and in Cav-1-enriched
intracellular vesicles. Most interestingly, following agonist ad-
ministration to induce internalization, little additional 5-HT2A
receptor internalization was induced in cells co-expressing Cav-1
(Fig. 1, D–F; see Fig. 1G for quantification).
We next performed co-immunoprecipitation studies in HEK-
293 cells co-transfected with FLAG-5-HT2A and Cav-1 to deter-
mine whether 5-HT2A receptors and Cav-1 interact. As can be
FIG. 4. RNAi-mediated knockdown of Cav-1. For these experi-
ments C6 glioma cells were transfected with pRNA-U6.1/Neo-RNAi-
Cav-1 vector, and clones were stably selected (see “Experimental Pro-
cedures” for details). A, representative immunoblot (IB) of five clonally
isolated cell lines screened for the presence of Cav-1 (equal amount of
protein was loaded in duplicates). B, representative immunoblot for
RNAi clone showing knockdown of protein Cav-1 with respect to wt C6
glioma cell lysates. Samples were loaded in duplicate and also probed
for total Gq and RSK1 to assess nonspecific knockdown of unrelated
proteins. C, representative immunoblot for RNAi clone showing knock-
down of protein Cav-2 with respect to wt C6 glioma cell lysates. Equal
amounts of protein were loaded in duplicate and, as a control, probed for
total Gq in the samples.
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seen, FLAG-tagged 5-HT2A receptors were co-immunoprecipi-
tated robustly with Cav-1 (Fig. 2, 9th to 12th lanes), indicating
that 5-HT2A receptors and Cav-1 associate with each other and
are present in a complex in vitro. To establish the specificity of
the interaction, we showed that cells co-transfected with Cav-1
and empty vector yielded minimal pull-down of Cav-1 (Fig. 2,
3rd and 4th lanes). Furthermore, no Cav-1 was pulled down
from untransfected cells (Fig. 2, 1st and 2nd lanes) or from cells
co-expressing 5-HT2A receptors and GFP (Fig. 2, 5th and 6th
lanes). The interaction of FLAG-5-HT2A and Cav-1 was unaf-
FIG. 5. Knockdown of Cav-1 expression impairs signaling of 5-HT2A receptors and P2Y purinergic receptors without altering
signaling of PAR-1 thrombin receptors. For these experiments wt C6 glioma cells and RNAi-mediated knocked down Cav-1 cells were plated
onto 96-well plates. Cells were place in serum-free media for a minimum of 18 h and then exposed to agonist as detailed previously (29). Left panel
shows the sigmoid dose response to various agonists (A–C, 5-HT, ATP, and TRAP, respectively) in normalized relative fluorescence units (RFU).
D shows the bar graph representing the maximal response of wt and Cav-1 knockdown C6 cell to calcium ionophore A23187. The panels on the right
show the changes in fluorescence of wt and RNAi-mediated Cav-1 knockdown C6 cells with time when exposed to vehicle, maximal agonist, and
calcium ionophore. (A–D, 5-HT, ATP, TRAP, and A23187, respectively). A shows the 5-HT-mediated dose response for calcium flux for wild-type
and Cav-1 knockdown cells; B shows the ATP-mediated dose response for calcium flux for wild-type and Cav-1 knockdown cells; C shows the
thrombin-mediated PAR-1 receptor response of wt C6 glioma and C6 Cav-1 RNAi cells; and D shows the maximal response of wt and Cav-1
knockdown cell response to calcium ionophore A23187.
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fected by agonist exposure (Fig. 2, compare 9th to 12th lanes).
These findings demonstrated that Cav-1 forms a complex with
5-HT2A receptors in an agonist-independent fashion.
We also examined whether 5-HT2A receptors and Cav-1 are
associated in a milieu in which both 5-HT2A receptors and
Cav-1 are endogenously expressed. Several cell lines reported
to express 5-HT2A receptors were tested including an aortic
smooth muscle cell line (A7R5 (30)), NIH 3T3 cells (31), and C6
glioma cells (13). As controls, we also examined HEK-293 cells,
which express little Cav-1, and GF-62 cells, which we have
demonstrated previously (21) express little Cav-1. We found
that C6 glioma cells expressed the highest levels of Cav-1, and
these were therefore chosen for further study.
Co-immunoprecipitation studies were then performed in C6
glioma cells and rat brain synaptic membrane preparations
wherein endogenous Cav-1 was immunoprecipitated, and the
immunoprecipitates were probed for endogenous 5-HT2A-like
immunoreactivity. Fig. 3B shows that 5-HT2A receptors were
co-immunoprecipitated with Cav-1 in C6 glioma cells, and Fig.
3C shows co-immunoprecipitation of native 5-HT2A receptors
by Cav-1 from solubilized rat brain synaptic membrane prep-
arations. As controls to verify the specificity of the interaction,
5-HT2A receptors were immunoprecipitated with protein-A/G
beads conjugated to agarose in the absence () and/or presence
of a monoclonal Cav-1 antibody (). Fig. 3B, top panel, 1st lane,
shows no immunoreactivity to 5-HT2A receptor antibody, and
the 2nd lane shows that 5-HT2A receptors were co-immunopre-
cipitated with Cav-1. The 2nd panel from the top of Fig. 3B
shows the 1st lane with minimal Cav-1 immunoreactivity (e.g.
negative control lane), and the 2nd lane shows a large amount
of Cav-1 was detected when Cav-1 was immunoprecipitated
(e.g. positive control lane). The 3rd panel from the top of Fig. 3B
shows representative immunoblots from cell lysates to detect
total Cav-1. The bottom panel of Fig. 3B shows 5-HT2A-like
immunoreactivity in C6 glioma lysates.
In rat brain membrane preparations 5-HT2A receptors were
immunoprecipitated with protein-A/G beads conjugated to aga-
rose without () or with a monoclonal Cav-1 antibody (). As
shown in Fig. 3C, top panel, 1st lane () shows no immunore-
activity to 5-HT2A receptor antibody, and the 2nd lane ()
shows that 5-HT2A receptors were co-immunoprecipitated with
Cav-1. The 2nd panel from the top of Fig. 3C shows the 1st lane
wherein minimal Cav-1 immunoreactivity to polyclonal Cav-1
antibody was detected in the negative control, and the 2nd lane
shows that Cav-1 in the immunoprecipitate was detected (e.g.
positive control). The 3rd panel from the top of Fig. 3C repre-
sents the immunoblots from the cell lysates to detect endoge-
nous Cav-1. The bottom panel of Fig. 3C represents the immu-
noblot from rat membrane preparation to verify the expression
of 5-HT2A receptors. Taken together, these results indicate that
5-HT2A receptors are complexed with Cav-1 in both transfected
cells and in their native milieu.
RNAi-mediated Knockdown of Cav-1 in C6 Glioma
Cells—We next examined whether Cav-1 functions as a phys-
iological modulator of 5-HT2A signaling by stably suppressing
the expression of Cav-1 in C6 glioma cells using RNAi-medi-
ated gene silencing. We clonally isolated 48 separate C6 lines
that survived selection, and we quantified the level of relative
Cav-1 expression by Western blot analysis. Shown in Fig. 4A
are representative results from five lines screened for Cav-1
expression. Fig. 4B shows representative results from one of
the surviving lines, clone 2 of the several screened for Cav-1
expression. All the signaling studies were subsequently carried
out with clone 2. The Cav-1 knockdown C6 glioma cells ap-
peared to be morphologically similar to wild-type C6 cells,
although they had a slower doubling time than wt C6 cells
(data not shown). In our initial studies we examined the rela-
tive expression of two unrelated proteins, Gq and ribosomal
S6 kinase-1 (RSK1), to determine the specificity of the RNAi-
mediated knockdown of Cav-1. We also examined the expres-
sion of Cav-2, another member of caveolin family of proteins. As
can be seen in Fig. 4B, both the parental and the RNAi-Cav-1
lines expressed similar amounts of Gq and RSK1. However, as
shown in Fig. 4C there is a significant down-regulation in the
expression of protein Cav-2 with no change in Gq protein
levels suggesting that the expression of Cav-2 protein is regu-
lated by Cav-1, as reported previously (33).
RNAi-mediated Knockdown of Cav-1 Profoundly Suppresses
5-HT2A-mediated Signaling—We next examined 5-HT2A-medi-
ated signal transduction in wt and Cav-1 knockdown C6 cells.
As shown in Fig. 5A, 5-HT2A-mediated intracellular Ca
2 mo-
bilization was nearly abolished in Cav-1 knockdown C6 cells.
To determine whether this represented a generalized effect on
Gq-mediated signaling, we performed a cDNA microarray ex-
periment to identify other Gq-coupled GPCRs that are endo-
genously expressed in C6 cells. As shown in Table I and in the
Supplemental Material, several other GPCRs were expressed,
including the P2Y purinergic receptor and the coagulation fac-
tor II receptor (PAR-1), both of which are coupled to Gq. Fig.
5B shows that the ATP-induced Ca2 transients induced by
P2Y purinergic receptor activation were also greatly attenu-
ated in Cav-1 knockdown C6 cells. However, the TRAP-induced
Ca2 flux mediated by PAR-1 was unaffected (Fig. 5C). Esti-
mates of agonist potency (EC50) and efficacy (Emax) values
revealed that Cav-1 knockdown altered the efficacy without
significantly altering potency (Table II). As a control, we also
examined the response induced by the calcium ionophore
A23187 response (Fig. 5D). These results indicate that Cav-1
modulates signaling of some but not all Gq-coupled receptors.
The results also imply that Cav-1 knockdown does not induce a
generalized dysfunction of Gq-mediated signaling.
RNAi-mediated Knockdown of Cav-1 Does Not Alter 5-HT2A
Receptor Binding or Expression—To address the possibility
that the impairment in 5-HT2A receptor signaling was a con-
sequence of decreased 5-HT2A receptor expression in Cav-1
knockdown cells, we concentrated the receptor protein by using
WGA-agarose and subjected the eluate to immunoblot analysis
in order to estimate receptor protein expression in Cav-1
knockdown cells versus wt C6 glioma cells. Total cell lysates
were also probed for Gq as a loading control. Fig. 6A shows a
representative immunoblot of 5-HT2A expression in wt C6 cells
TABLE I
Microarray analysis of rat C6 glioma cells reveals the
expression of selected GPCRs
Shown are the gene title and gene symbols for various GPCRs iden-
tified by microarray analysis of C6 glioma mRNA as being present (see
Supplemental Material for details).
Gene title Gene symbol
5-Hydroxytryptamine (serotonin) receptor 2A Htr2a
Thyroid-stimulating hormone, receptor Tshr
Bradykinin receptor B1 Bdkrb1
Endothelial differentiation, sphingolipid G-
protein-coupled receptor, 5
Edg5
Muscarinic receptor m2 Chrm2
Opsin 1 (cone pigments), medium wave-sensitive
(color blindness, deutan), green opsin
Opn1mw
G-protein-coupled receptor 48 Gpr48
Arginine vasopressin receptor 1B Avpr1b
Coagulation factor II receptor (PAR-1) F2r
Putative G-protein-coupled receptor Gpr
Purinergic receptor P2Y, G-protein-coupled 2 P2ry2
G-protein-coupled receptor 30 Gpr30
Adrenergic receptor, 2 Adrb2
Dopamine receptor D3 Drd3
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and Cav-1 knockdown cells; as can be seen the Cav-1 knock-
down cells expressed slightly more 5-HT2A-like immunoreac-
tivity as assessed by Western blot analysis. We also performed
radioligand binding assays using [3H]ketanserin, a selective
5-HT2A radioligand in both sets of cells. As shown in Table II
there was no significant change in maximal binding potential
of 5-HT2A receptor in wt C6 cells and Cav-1 knockdown C6 cells
(p value  0.05) or affinity of 5-HT2A receptors for ketanserin.
These data demonstrate that the impairment in signaling of
5-HT2A receptors in Cav-1 knockdown cells is not a conse-
quence of altered receptor expression.
RNAi-mediated Knockdown of Cav-1 Induces a Dysregula-
tion of p42/44 MAP Kinase Activity—We next examined
5-HT2A-mediated p42/44 MAP kinase phosphorylation in re-
sponse to agonist in wt C6 glioma cells and Cav-1 knockdown
C6 cells. Fig. 7A is a representative immunoblot that shows an
apparent increase in basal p42/44 phosphorylation in Cav-1
knockdown cells, whereas the total ERK levels were equivalent
within each set (Fig. 7B). Exposure to 10 M 5-HT for 5 min
increased p42/44 ERK phosphorylation in wild-type but not in
Cav-1 knockdown cells. Fig. 7C depicts the quantification of the
increase in phosphorylation upon 5-HT exposure over basal
(normalized to total ERK). The average data from three inde-
pendent experiments showed a significant decrease (p  0.05)
in p42/44 ERK phosphorylation levels upon agonist exposure in
Cav-1 knockdown cells when normalized to total ERK. Our
data show that upon 5-HT exposure there is an increase in
phospho-ERK that is equivalent in both wt and Cav-1 knock-
down C6 cells. As shown in Fig. 7D, the data are represented as
a 5-HT-induced increase in phospho-ERK normalized to wt
basal, where the maximal increase in phospho-ERK is signifi-
cantly increased (p  0.05) in both wt and Cav-1 knockdown C6
glioma cells.
Cav-1 Overexpression Minimally Affects Gq*-mediated Ac-
tivation of Phospholipase C—To investigate the possibility that
Cav-1 modulates the phospholipase C signaling pathway by
associating with downstream effectors (i.e. Gq and phospho-
lipase C), we examined whether Cav-1 modulated inositol phos-
phate accumulation in HEK-293 cells transiently expressing a
constitutively active form of Gq (Gq*) with GFP and or Cav-1.
Gq* activates phospholipase C and elevates immunoprecipi-
tation levels independent of the activation of Gq-coupled re-
ceptors (32). In the absence of 5-HT2A receptors, overexpression
of Cav-1 modestly but significantly attenuated the Gq*-stim-
ulated inositol phosphate accumulation when compared with
GFP alone (p  0.05; Fig. 8A). It has been reported previously
that the association of Cav-1 with G-proteins invariably atten-
uates their activity. Most importantly, Cav-1 did not cause any
change in the relative expression of Gq* (Fig. 8B). These
findings support the hypothesis that Cav-1 modulates intracel-
lular signaling at the level of receptor-effector coupling and not
via a receptor-independent attenuation of Gq signaling.
Caveolin-1 Potentiates the Interaction between Gq and
5-HT2A Receptors—To investigate further the role of Cav-1 in
modulation of 5-HT2A receptor signaling, we performed immu-
noprecipitation studies in HEK-293 cells co-transfected with
5-HT2A receptors and Gq in the presence and absence of
Cav-1. Forty-eight hours post-transfection cells were serum-
starved for 18 h and exposed to agonist for various times. Cells
were then lysed, and 5-HT2A receptors were immunoprecipi-
tated as described earlier (see “Experimental Procedures”), and
Gq was detected in the immunoprecipitates using anti-Gq
antibody (Fig. 9A). Immunoblot analysis showed that in pres-
ence of Cav-1 there is a significant increase of Gq detected in
the immunoprecipitates under conditions of no agonist and at 2
min after agonist exposure (Fig. 9A compare the 4th and 5th
with the 7th and 8th lanes). Fig. 9B shows the quantitative
analysis of the net pixel intensities of bands from three inde-
pendent experiments normalized to the total Gq in the lysate.
The data show a significant increase in Gq in the immunopre-
cipitates in presence of Cav-1. These findings imply that Cav-1
plays a major role in modulating the signaling of 5-HT2A re-
ceptors by promoting a functional interaction between 5-HT2A
receptors and Gq.
TABLE II
RNAi-mediated knockdown of Cav-1 modulates 5-HT2A-serotonin and P2Y purinergic but not PAR-1-thrombin receptor-mediated signaling
Agonist potencies (EC50) and efficacies (Emax) were determined for agonist-mediated activation of intracellular Ca
2 mobilization as described
under “Experimental Procedures.” Data from radioligand binding assays include estimates of affinity (Kd in nM) and the maximal receptor number
(Bmax in fmol/mg) for [
3H]ketanserin. The results represent the average of three independent experiments.
Pharmacological parameters
5-HT2A P2Y PAR-1

















1.00  0.00 0.10  0.01a 1.00  0.07 0.16  0.12a 0.77  0.04b 1.00  0.05
Kd  S.E. 14.5  9.0 14.4  11.5
b NDc ND ND ND
Maximal specific binding
Bmax  S.E.
55.7  17.4 76.3  38.4b ND ND ND ND
a Comparison with wt C6 glioma cells, p  0.0001.
b Comparison with wt C6 glioma cells, no statistically significant difference.
c ND, not determined.
FIG. 6. Knockdown of Cav-1 expression has no effect on 5-HT2A
protein expression. For these experiments wt C6 glioma cells and
Cav-1 knockdown cells were prepared for immunoblot (IB) analysis and
radioligand binding assays as described previously. Shown here is a
representative immunoblot, which reveals a modest increase in expres-
sion of WGA affinity-purified 5-HT2A receptors in RNAi-knockdown
Cav-1 cells as compared with wt C6 cells.
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DISCUSSION
The major findings of the present work are that Cav-1 asso-
ciates with 5-HT2A receptors in vivo and in vitro, promotes the
association of 5-HT2A receptors with Gq, and that the RNAi-
mediated knockdown of Cav-1 profoundly impairs signaling of
5-HT2A receptors and selected Gq-coupled GPCRs. Caveolin-1
has thus emerged as a novel modulator of 5-HT2A receptor
signaling. We also demonstrate that the RNAi-mediated knock-
down of Cav-1 expression in C6 glioma cells profoundly impairs
signaling for extracellular ATP acting on P2Y purinergic recep-
tors without altering PAR-1 thrombin receptor-mediated sig-
naling. Taken together, these results imply that Cav-1 plays a
major role in modulating the signal transduction of selected
Gq-coupled GPCRs. We also show that the impairment of
signaling in Cav-1 knockdown cells was not a consequence of
altered receptor or Gq protein content. Additionally, our stud-
ies with a constitutively active Gq imply that Cav-1 does not
directly potentiate Gq signaling. Instead, our results suggest
that Cav-1 facilitates functional interactions between Gq and
selected GPCRs.
Prior studies by Razani et al. (33) in Cav-1 null mouse fibro-
blasts have shown that in the absence of Cav-1 there is a
drastic reduction in Cav-2 levels because Cav-2 is not targeted
to the membrane and is subsequently degraded intracellularly.
In another study, an antisense strategy used to deplete Cav-1
in NIH 3T3 cells had no effect on expression of Cav-2 (34). In
our present study we report that the stable knockdown of Cav-1
had no significant effect on the mRNA levels of Cav-2; Cav-3
was not measured because it is not expressed in C6 glioma cells
(microarray data not shown). However, we report a significant
reduction in Cav-2 protein expression suggesting that Cav-2
protein is degraded in Cav-1 knockdown C6 glioma cells, as
FIG. 7. Knockdown of Cav-1 expression induces a dysregula-
tion of basal and agonist-stimulated p42/44 ERK phosphoryla-
tion. For these experiments wt C6 cells endogenously expressing
5-HT2A receptors and Cav-1 and RNAi-mediated knockdown Cav-1 cells
were used. Cells were put into serum-free media for a minimum of 18 h
and then exposed to vehicle () or 10 M 5-HT () for 5 min. Lysates
were prepared (see “Experimental Procedures”) and subjected to immu-
noblot analysis and probed for pERK42/44 total ERK42/44 levels. Rep-
resentative immunoblots from a single experiment that has been rep-
licated three times with equivalent results are shown. A, immunoblot
pERK42/44; B, immunoblot ERK42/44; C, quantification of the net pixel
intensities of p42/44 ERK normalized to total 42/44 ERK; D, data
represent an increase in pixel intensity on 5-HT exposure of p42/44
ERK normalized to wt basal.
FIG. 8. Cav-1 overexpression modestly attenuates Gq signal-
ing. For these experiments, a constitutively active form of Gq (Q229L
or Gq*) was co-transfected with either GFP or Cav-1myc in HEK-293
cells. A, Cav-1 (Cav-1  Gq*) modestly attenuates Gq*-stimulated
inositol phosphate accumulation over Gq*  GFP in the absence of
5-HT2A receptors. B shows a representative immunoblot of total Gq
from all sample groups (in duplicate). Results shown represent the
mean (S.E.) of three independent experiments.
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shown previously (33) for mouse embryonic fibroblasts from
Cav-1 knockout mice.
Cav-1 is an integral membrane protein, which associates
with numerous lipid-modified signaling molecules including
Ha-Ras, c-Src, and endothelial nitric-oxide synthase, and al-
most invariably attenuates the activity of the signaling mole-
cule when overexpressed (35, 36). Additionally, Cav-1 directly
interacts with the EGF receptor and inhibits its activity (37),
and such an interaction leads to internalization of EGF recep-
tor via caveolar domains (38). More recent studies have shown
that transcriptional up-regulation of Cav-1 in senescent cells
attenuates EGF-mediated signaling thus implicating the role
of Cav-1 in EGF receptor-mediated signaling and the general
unresponsiveness of senescent cells to growth stimuli (39). The
ability of Cav-1 to regulate oncogenes and the downstream
signaling cascades has been observed in many overexpression
studies wherein Cav-1 is a potent inhibitor of the Ras-p42/44
MAP kinase cascade (40). On the other hand antisense-medi-
ated down-regulation of Cav-1 leads to hyperactivation of the
p42/44 MAP kinase cascade (34). These studies suggest that
Cav-1 is a modulator of multiple signaling cascades. In this
regard, we found that Cav-1 knockdown in C6 glioma cells
significantly elevates basal p42/44 ERK phosphorylation and
impairs 5-HT2A agonist-mediated p42/44 ERK phosphoryla-
tion. Thus, Cav-1 knockdown appears to induce a dysregulation
of GPCR-mediated p42/44 ERK phosphorylation.
Our results are especially intriguing in light of a recent study
that has indirectly implicated caveolae in 5-HT2A-mediated
signal transduction (22) in vascular smooth muscle cells. In
those studies, the authors reported that 5-HT2A receptors were
enriched in “lipid rafts” isolated by sucrose density gradients.
We have also found that a small fraction of 5-HT2A receptors is
located in the caveolar fraction when Cav-1 is overexpressed in
HEK-293 cells and in C6 glioma cells where both proteins are
endogenously expressed.2 The localization of other GPCRs such
as B2 bradykinin receptors (41) and 1- and 2-adrenergic
receptors in the caveolar fraction has been reported previously
(42), where the role of caveolae has been implicated as traffick-
ing centers where GPCRs translocate into or out of the caveo-
lae. Our findings that the effect of Cav-1 knockdown is seen
with at least one other Gq-coupled GPCR family (P2Y puri-
nergic receptors) and not with PAR-1 implies that Cav-1 selec-
tively modulates Gq-coupled receptor signaling, perhaps by
promoting association with Gq.
Recent in vivo studies with Cav-1 knockout mice (19) suggest
an indispensable role of Cav-1 in normal life span and cardiac,
pulmonary, and vascular functioning (43, 44). Our studies,
wherein Cav-1 is knocked down, revealed that in the absence of
Cav-1 the signalings of 5-HT2A and P2Y receptors were nearly
totally abolished. Because 5-HT2A receptors represent the prin-
cipal vascular smooth muscle 5-HT receptor and a main pul-
monary and cardiac 5-HT receptor, and because purinergic
receptors are ubiquitously expressed, our results suggest that
the profound cardiovascular phenotype found in Cav-1 knock-
out mice may result, in part, from impaired serotonergic and
purinergic signaling.
A preliminary microarray analysis of Cav-1 knockdown C6
glioma cells shows that the Cav-1 knockdown cells exhibited no
global changes in gene expression compared with the parental
cells, although Cav-1 but not Cav-2 mRNA was significantly
diminished (not shown). Most important, mRNA levels for
5-HT2A serotonin receptors and PAR-1 receptors remained un-
changed along with the relative mRNA levels for all of the
various proteins involved in Gq-mediated signaling (not
shown). However, the mRNA encoding the P2Y2 purinergic
receptors was absent in Cav-1 knockdown cells and present in
wt C6 cells. Most intriguingly, for another Gq-coupled P2Y
receptor subtype (P2Y5), the steady-state mRNA levels remain
unchanged in parental and Cav-1 knockdown cells (not shown).
The selective knockdown of P2Y2 likely accounts for at least
some of the decreased response to ATP seen in the Cav-1
knockdown cells. The precise role of Cav-1 in selectively regu-
lating the expression of a single subtype of P2Y family recep-
tors (e.g. P2Y2 and not P2Y5) will require further study.
In summary we have discovered a novel role for Cav-1 in
regulating the activity of serotonergic and purinergic receptors
but not thrombinergic Gq-coupled receptors. Our results indi-
cate that Cav-1 associates with the 5-HT2A receptors in vitro
(HEK-293 and C6 cells) and in vivo (rat brain synaptic mem-
branes) and that this interaction has profound functional sig-
nificance. Given the widespread distribution of serotonergic
receptors (e.g. platelets, gastrointestinal smooth muscle, uter-
ine smooth muscle, kidneys, the cardiovascular system, and the
brain) and the correspondingly ubiquitous distribution of
Cav-1, it is likely that the 5-HT2A-Cav-1 interactions represent
a functionally significant protein-protein interaction of poten-
tially profound biological significance.
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FIG. 9. Cav-1 potentiates 5-HT2A receptor interactions with
Gq in absence of agonist. For these experiments, Gq was co-
transfected with 5-HT2A receptors and either GFP or Cav-1 in HEK-293
cells. Cells were put in serum-free media for a minimum of 18 h, and
then exposed to vehicle (0) or 10 M 5-HT for 2 and 5 min. Lysates were
prepared and subjected to immunoprecipitation (IP) using M2 FLAG
preconjugated agarose (“Experimental Procedures”). A, shown is a rep-
resentative immunoblot (IB) from a single experiment that has been
replicated three times with equivalent results. B, quantification of the
net pixel intensities of Gq in the immunoprecipitates normalized to
total Gq. Each set was then normalized to the maximum in each set.
Result shown here are the means  S.E. from all three experiments.
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